Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation announced its financial results for Q1 2022, reporting total net revenue of $94.6 million, a 33% decline year-over-year. The U.S. market faced challenges from three generic entrants, resulting in a 34% decrease in net product revenue. However, the company made progress in its European expansion strategy, securing national reimbursement for VAZKEPA in Sweden and initiating reimbursement discussions in several European markets. Despite the revenue drop, Amarin aims to maximize VASCEPA's value and is committed to operational excellence.
The latest REDUCE-IT study analysis published in JACC highlights the significant cardiovascular benefits of VASCEPA (icosapent ethyl) for patients with a history of myocardial infarction (MI). The study found a 35% reduction in total ischemic events, including 34% in non-fatal MI and 30% in cardiovascular deaths. Conducted on 3,693 patients, this sub-analysis reinforces icosapent ethyl as an essential treatment for mitigating severe cardiovascular risks in high-risk patients. The safety profile showed consistent results, with some increased risks of atrial fibrillation and minor bleeding.
Amarin Corporation (NASDAQ:AMRN) announced that its partner HLS Therapeutics has finalized negotiations with Canada's pan-Canadian Pharmaceutical Alliance for the public reimbursement of VASCEPA® (icosapent ethyl). A Letter of Intent was signed, allowing HLS to pursue coverage across Canadian provinces. This milestone aims to enhance access for statin-treated patients with cardiovascular disease and elevated triglycerides. The exclusive commercialization agreement includes payments up to $65 million to Amarin, along with tiered royalties on VASCEPA sales in Canada.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on May 4, 2022, at 8:00 a.m. ET, to discuss its first quarter 2022 financial results. This call follows the anticipated release of the financial results earlier that day. Investors can access the live call via the investor relations section of Amarin's website or by dialing in. The company is focused on advancing cardiovascular disease management and has a global presence with offices in multiple countries.
Amarin Corporation (NASDAQ: AMRN) announced significant findings from an in vitro trial presented at the ACC’s 71st Annual Scientific Session. The study revealed that combinations of Eicosapentaenoic Acid (EPA) with statins—atorvastatin and rosuvastatin—reduced lipid oxidation by 86% and 75%, respectively (p<0.001). These results enhance the understanding of EPA's role in combating cardiovascular risks when paired with statins, aligning with previous REDUCE-IT trial results. The trial emphasizes potential benefits for high-risk patients needing stronger solutions.
Amarin Corporation plc (NASDAQ:AMRN) achieved a significant milestone by securing its first national reimbursement for VAZKEPA in Sweden, marking an important phase in its international expansion strategy. The Swedish Dental and Pharmaceutical Benefits Agency approved VAZKEPA for statin-treated patients with established cardiovascular disease at a monthly cost of 1,640 SEK. The company aims to expand its presence in several other European countries and is actively pursuing regulatory approvals in markets like Australia, New Zealand, and Saudi Arabia. This decision is expected to unlock significant revenue potential for Amarin.
Amarin Corporation has announced research on VASCEPA and VAZKEPA to be presented at the American College of Cardiology’s 71st Annual Scientific Session from April 2-4, 2022. Six posters will highlight findings related to the effectiveness of icosapent ethyl in reducing cardiovascular risks, particularly when combined with high-intensity statins. CEO Karim Mikhail expressed optimism about the continuous expansion of the evidence base regarding icosapent ethyl's potential role for high-risk patients.
Amarin Corporation announced that a new post hoc analysis of the REDUCE-IT study indicates that VASCEPA significantly reduces cardiovascular risks in patients with a history of percutaneous coronary intervention (PCI). The analysis showed a 34% reduction in major cardiovascular events, with absolute risk reductions of 8.5% and 5.4% for primary and secondary endpoints. In total, 3,408 patients were involved, where 37.6% on standard care had major events compared to 25.6% treated with VASCEPA. The findings support VASCEPA's role in reducing recurrent cardiovascular events in high-risk patients.
Amarin Corporation plc (NASDAQ:AMRN) reported a 2021 net revenue of $583.2 million, down 5% from 2020. The net product revenue was $580.3 million, impacted by generic competition and COVID-19 effects. In the U.S., the Go-To-Market strategy is progressing well, with expanded reach to 150,000 healthcare providers. Meanwhile, VAZKEPA has received approval in Europe, and Amarin is advancing regulatory filings in multiple countries. The company remains committed to enhancing cardiovascular outcomes and managing operational costs effectively. A conference call is scheduled for today at 8:00 a.m. ET.
Amarin Corporation (NASDAQ: AMRN) announced that CEO Karim Mikhail will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on March 7, 2022, from 9:10 AM to 9:40 AM ET. Interested parties can access the live webcast on the company’s investor relations website, which will be archived for 30 days. Amarin focuses on innovative cardiovascular disease management and clinical trials, with a commitment to advancing treatment options.